The FDA is already evaluating a similar request for another pill from Merck, a competitor to Pfizer, and plans to hold a public meeting on the subject at the end of the month.
The price of treatment with Pfizer’s Paxlovid pill will be around $ 529, the company said in a statement.
The United States has already agreed to pay about $ 700 for each treatment with Merck’s Molnupiravir pill.
Pfizer also said that it has already begun to apply for approval of the emergency use of its pill in several other countries and that other purchase agreements from different governments are well advanced, CNN reported.
Two days ago, Pfizer signed an agreement with a UN-sponsored initiative to allow generic drug labs to produce cheap versions of its anticovid pill for certain countries.
Merck signed a similar deal for its own pill, which was licensed in the UK earlier this month.
Pfizer reported this month that its pill reduces hospitalization or death by nearly 90% among newly infected unvaccinated or high-risk patients.
Pfizer has already reported global revenue of more than $ 24 billion this year from the sale of its coronavirus vaccine, which quickly became the company’s best-selling drug.
Source From: Ambito
David William is a talented author who has made a name for himself in the world of writing. He is a professional author who writes on a wide range of topics, from general interest to opinion news. David is currently working as a writer at 24 hours worlds where he brings his unique perspective and in-depth research to his articles, making them both informative and engaging.
